Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | TERT | O14746 | 13/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805514 | 1.00 | CCR1 (0.40) | CCR1TERTF2RPGK1PGK2 | |
| SCHEMBL9868200 | 0.86 | SMN1; SMN2 (0.41) | CCR1TERTALDH1A1 | |
| SCHEMBL12664449 | 0.83 | KCNH2 (0.45) | CCR1TERTPGK1PGK2ALDH1A1 | |
| SCHEMBL29953038 | 0.79 | CCR1 (0.40) | CCR1TERTPGK1PGK2ALDH1A1 | |
| SCHEMBL22354808 | 0.79 | CCR1 (0.40) | CCR1TERTPGK1PGK2ALDH1A1 | |
| SCHEMBL249047 | 0.79 | CCR1 (0.40) | CCR1TERTF2RALDH1A1 | |
| SCHEMBL29951735 | 0.79 | CCR1 (0.40) | CCR1TERTPGK1PGK2ALDH1A1 | |
| SCHEMBL6984612 | 0.79 | CCR1 (0.40) | CCR1TERTPGK1PGK2ALDH1A1 | |
| SCHEMBL9561000 | 0.79 | CCR1 (0.40) | CCR1TERTPGK1PGK2ALDH1A1 | |
| SCHEMBL2928608 | 0.79 | CCR1 (0.40) | CCR1F2RPGK1PGK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101475-A1 | MONOOXYGENASE MUTANTS FOR BIOSYNTHESIS OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE AND A METHOD FOR PREPARATION OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE USING THE SAID MONOOXYGENASE MUTANTS | VIO CHEMICALS AG (CH) | 2025-03-27 | — | — | US | disclosed |
| US-11945838-B2 | Method for synthesis of protein amphiphiles | INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IN) | 2024-04-02 | — | — | US | disclosed |
| CN-115057836-B | Ester compound and preparation method and application thereof | 浙江糖能科技有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-114656431-B | Alpha, beta-unsaturated ketone compound, and preparation method and application thereof | 浙江糖能科技有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20230250456-A1 | METHOD FOR PREPARATION OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE VIA ENZYMATIC CATALYSIS | VIO CHEMICALS AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250456-A1 | METHOD FOR PREPARATION OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE VIA ENZYMATIC CATALYSIS | VIO CHEMICALS AG (CH) | 2023-08-10 | — | — | US | disclosed |
| WO-2023126510-A1 | MONOOXYGENASE MUTANTS FOR BIOSYNTHESIS OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE AND A METHOD FOR PREPARATION OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE USING THE SAID MONOOXYGENASE MUTANTS | VIO CHEMICALS AG (CH) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023126510-A1 | MONOOXYGENASE MUTANTS FOR BIOSYNTHESIS OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE AND A METHOD FOR PREPARATION OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE USING THE SAID MONOOXYGENASE MUTANTS | VIO CHEMICALS AG (CH) | 2023-07-06 | — | — | WO | disclosed |
| US-11685741-B2 | Fluorescent probes | UNIVERSITY OF MASSACHUSETTS (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685741-B2 | Fluorescent probes | UNIVERSITY OF MASSACHUSETTS (US) | 2023-06-27 | — | — | US | disclosed |
| US-6703373-B1 | ANTICARCINOGENIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | ANORMED INC. (CA) | 2002-04-25 | — | — | US | disclosed |
| EP-1163247-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056743-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
| EP-0763033-A1 | IMIDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995032198-A1 | IMIDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1995-11-30 | — | — | WO | disclosed |
| EP-0533695-B1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY | PFIZER (US) | 1994-10-05 | — | — | EP | disclosed |
| US-5322847-A | Inhibit platelet activating factor, block leukotriene D4 receptors | PFIZER INC. (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0533695-A1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY. | PFIZER (US) | 1993-03-31 | — | — | EP | disclosed |
| WO-1991017163-A1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250456-A1 | METHOD FOR PREPARATION OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE VIA ENZYMATIC CATALYSIS | DCXR, LOX, XDH | CCR1 2292/4885TERT 2863/4885F2R 817/4885 |
| US-11685741-B2 | Fluorescent probes | FECH, CHERP, SLC40A1 | CCR1 4362/4885TERT 3951/4885F2R 4184/4885 |
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | CFD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12 | CCR1 378/4885TERT 3143/4885F2R 1118/4885 |
| US-11945838-B2 | Method for synthesis of protein amphiphiles | PTMS, VAC14, PDIA6 | CCR1 3640/4885TERT 3130/4885F2R 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.